Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

Takeyama, Masahiro; Sasai, Kana; Matsumoto, Tomoko; Furukawa, Shoko; Ogiwara, Kenichi; Yada, Koji; Onishi, Tomoko; Shima, Midori; Nogami, Keiji

doi:10.1007/s12185-021-03249-w

Cited by 7 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 C). |min1| and |min2| represent the maximum coagulation rate and maximum acceleration of the coagulation rate, respectively [ 9 ]. These comprehensive coagulation tests suggested that her coagulation capacity was only slightly impaired.…”

Section: Case Descriptionmentioning

confidence: 99%

Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?

Hosoi¹,

Tane²,

Kosako³

et al. 2022

Journal of Autoimmunity

Self Cite

View full text Add to dashboard Cite

Section: Case Descriptionmentioning

confidence: 99%

Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?

Hosoi¹,

Tane²,

Kosako³

et al. 2022

Journal of Autoimmunity

Self Cite

View full text Add to dashboard Cite

“…Although the mechanisms of action of these anticoagulants suggest a desired anticoagulant effect when combined with emicizumab, there is no evidence for a balance between coagulation and fibrinolysis in plasma from PwHA. We have previously reported on the comprehensive coagulation‐fibrinolytic potentials and their balance in PwHA plasma using two comprehensive assays, clot‐fibrinolysis waveform analysis (CFWA) 20 and thrombin and plasmin generation assay (T/P‐GA) 21,22 . In the present study, we evaluated the coagulation‐fibrinolysis potentials and their balance in PwHA plasma supplemented with emicizumab and anticoagulants in vitro that may be used in antithrombotic therapy, by using CFWA and T/P‐GA.…”

Section: Introductionmentioning

confidence: 99%

The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A

Onishi,

Harada,

Shimo

et al. 2023

Haemophilia

Self Cite

View full text Add to dashboard Cite

IntroductionEmicizumab is used as hemostatic prophylaxis for patients with hemophilia A (PwHA), irrespective of the presence of inhibitors. Although bacterial infection can lead to a procoagulant state, there is limited information on coagulation and fibrinolysis potentials in emicizumab‐treated PwHA and on the use of anticoagulants in such cases.AimWe examined whether anticoagulants affect the coagulation and fibrinolysis potentials in plasma from PwHA spiked with emicizumab.MethodsPlasma from PwHA was in vitro supplemented with emicizumab (50 μg/mL; emi‐plasma) and anticoagulants (recombinant thrombomodulin (rTM), nafamostat mesylate (NM), unfractionated heparin (UFH), or low‐molecular‐weight heparin (LMH)). PwHA plasma spiked with rFVIII (1 IU/mL) was used as a reference (ref‐plasma). The coagulation and fibrinolysis potentials in plasma was measured by thrombin and plasmin generation assay (T/P‐GA) and clot‐fibrinolysis waveform analysis (CFWA).ResultsIn T/P‐GA and CFWA, coagulation potentials (maximum coagulation velocity; |min1|, and peak thrombin; Th‐Peak) in plasma rose with increasing concentrations of emicizumab and rFVIII, but fibrinolytic potentials (peak plasmin; Plm‐Peak, and maximum fibrinolytic velocity; |FL‐min1|) remained unchanged. Adding rTM, NM, and UFH to emi‐plasma suppressed coagulation and fibrinolysis potentials, similar to ref‐plasma. Regarding the heparin, UFH and LMH inhibited the improved coagulation in emi‐plasma. UFH inhibited fibrinolysis as well, but LMH did not.ConclusionsAnticoagulants could exhibit the inhibitory effects on the coagulation and fibrinolysis potentials in plasma from PwHA spiked with emicizumab, similar to those in normal plasma.

show abstract

High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials

et al. 2023

View full text Add to dashboard Cite

Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

Cited by 7 publications

References 35 publications

Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?

Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?

The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A

High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials

Contact Info

Product

Resources

About